Arvinas (NASDAQ: ARVN) — Perfil da empresa, notícias e dados financeiros
Arvinas develops protein degradation therapeutics aimed at treating cancer and other diseases using their PROTAC® technology.
Arvinas
Arvinas (NASDAQ:ARVN) focuses on developing protein degradation therapeutics aimed at fighting cancer and other diseases. This innovative approach seeks to use the body's own machinery to degrade and remove disease-causing proteins. Their projects revolve around leveraging their proprietary PROTAC® Discovery Engine to advance a pipeline of novel drug candidates that have the potential to bring new treatments to patients in need. Arvinas' objectives center on progressing these drug candidates through clinical trials, with a strong emphasis on those targeting prostate and breast cancer. By harnessing the power of protein degradation, Arvinas aims to create a new class of drugs that could provide significant benefits over traditional therapies.
Resumo
Operações
Produtos e/ou serviços de Arvinas
- PROTAC Protein Degraders - A novel class of drugs that target disease-causing proteins for degradation.
- ARV-110 for Prostate Cancer - An investigational PROTAC protein degrader targeting androgen receptor (AR) driven diseases.
- ARV-471 for Breast Cancer - A pioneering PROTAC protein degrader specifically aiming at estrogen receptor (ER) positive diseases.
- Drug Discovery Platform - A versatile platform for developing a broad range of PROTAC-based therapies targeting various diseases.
- Partnerships in Pharma - Collaborations with larger pharmaceutical companies to expand the application and development of PROTAC technology.
- Clinical Development Program - A comprehensive program dedicated to advancing the clinical trials of PROTAC-based therapies for various cancers.
equipe executiva do Arvinas
- Andrew R. SaikCFO & Treasurer
- Angela M. CacaceChief Scientific Officer
- Randy TeelCEO, President & Director
- David K. LoomisVP & Chief Accounting Officer
- Jeff BoyleVice President of Investor Relations
- Jared M. FreedbergGeneral Counsel & Corporate Secretary
- Steve WeissSenior VP & Chief Human Resources Officer
- Kelly PageSenior VP & Global Head of Oncology Strategy and Program Leadership
Principais indicadores financeiros
Resultados divulgados pela Arvinas, em USD.
- Cap. de mercado
- 496,9 mi
- Receita (TTM)
- 316,7 mi
- P/L
- 29.2
- LPA (diluído, TTM)
- 0.3
- Dividend yield
- —
- Margem de lucro
- 2.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 262,6 mi | -114,9 mi | -80,8 mi | |
| 263,4 mi | -250,2 mi | -198,9 mi | |
| 78,5 mi | -401,5 mi | -367,3 mi | |
| 131,4 mi | -263,2 mi | -271,9 mi |